Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Factor VIII structure and function.

Philip J Fay1

  • 1Department of Biochemistry and Biophysics, University of Rochester School of Medicine, New York 14642, USA. philip_fay@urmc.rochester.edu

International Journal of Hematology
|March 4, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Noncovalent stabilization of the factor VIII A2 domain enhances efficacy in hemophilia A mouse vascular injury models.

Blood·2014
Same author

Effects of replacement of factor VIII amino acids Asp519 and Glu665 with Val on plasma survival and efficacy in vivo.

The AAPS journal·2014
Same author

Cofactor activity in factor VIIIa of the blood clotting pathway is stabilized by an interdomain bond between His281 and Ser524 formed in factor VIII.

The Journal of biological chemistry·2014
Same author

Residues flanking scissile bonds in Factor VIII modulate rates of cleavage and proteolytic activation catalyzed by Factor Xa.

Biochemistry·2013
Same author

Replacing the factor VIII C1 domain with a second C2 domain reduces factor VIII stability and affinity for factor IXa.

The Journal of biological chemistry·2013
Same author

Modification of interdomain interfaces within the A3C1C2 subunit of factor VIII affects its stability and activity.

Biochemistry·2013
Same journal

Cytarabine-based induction and oral maintenance therapy for a single system with single-site Langerhans cell histiocytosis.

International journal of hematology·2026
Same journal

Long-term treatment-free remission in CML after early dasatinib discontinuation due to interstitial pneumonitis.

International journal of hematology·2026
Same journal

Correction to: Low reticulocyte count at infusion is a risk factor for high-grade cytokine release syndrome in chimeric antigen receptor T cell therapy.

International journal of hematology·2026
Same journal

The efficacy of prophylactic tranexamic acid in patients with hematologic malignancy: a systematic review and meta-analysis.

International journal of hematology·2026
Same journal

Current status and challenges of TCR-T cell therapy for AML/MDS.

International journal of hematology·2026
Same journal

Efficacy and safety of maribavir in Japanese patients with post-transplant cytomegalovirus infections: a phase III study.

International journal of hematology·2026
See all related articles

Factor VIII (FVIII) is a crucial blood clotting protein stabilized by metal ions. Its activation by thrombin forms factor VIIIa, which, despite its importance in coagulation, is unstable and regulated by specific mechanisms.

Area of Science:

  • Biochemistry
  • Hematology
  • Molecular Biology

Background:

  • Factor VIII (FVIII) is a procofactor essential for blood coagulation.
  • It circulates as an inactive heterodimer stabilized by metal ions like copper and calcium.
  • Thrombin-mediated activation converts FVIII into the active cofactor, FVIIIa.

Purpose of the Study:

  • To elucidate the structural and functional aspects of Factor VIII activation and its role in the intrinsic factor Xase complex.
  • To understand the mechanisms governing the stability and regulation of Factor VIIIa.

Main Methods:

  • The study likely involves biochemical assays to analyze protein interactions and enzymatic activity.
  • Structural analysis may be employed to understand the conformation changes during activation.

Related Experiment Videos

  • Proteolytic cleavage studies could investigate the mechanisms of inactivation.

    • Main Results:

    • Factor VIII activation by thrombin involves specific exosites and metal ion interactions.
    • Factor VIIIa is a labile cofactor due to the weak association of its A2 subunit.
    • The intrinsic factor Xase complex, including FVIIIa and Factor IXa, significantly enhances Factor X conversion to Factor Xa.
    • Down-regulation involves A2 subunit dissociation and activated protein C-mediated proteolysis.

    Conclusions:

    • Factor VIII activation and function are intricately regulated processes critical for hemostasis.
    • The instability of FVIIIa highlights the importance of its regulatory mechanisms for preventing uncontrolled coagulation.
    • Understanding these mechanisms provides insights into bleeding disorders and potential therapeutic targets.